ABBV vs AVGO: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Broadcom Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-06.
AbbVie Inc. Β· Healthcare
$261.07
+1.2% upside to fair value
Grade C High Quality
VS
Broadcom Inc. Β· Technology
$379.86
-41.0% upside to fair value
Grade C High Quality
QuantHub Verdict
ABBV has more upside to fair value (+1.2%). AVGO trades at a lower forward P/E (61.3x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ABBV AVGO
Current Price $261.07 $379.86
Fair Value Estimate $264.30 $223.93
Upside to Fair Value +1.2% -41.0%
Market Cap $461.3B $1,806.8B
Forward P/E 128.0x 61.3x
EV / EBITDA 31.0x 44.1x
Price / Sales 7.3x 23.9x
Price / FCF 22.1x 55.2x
Revenue Growth YoY +12.4% +47.9%
Gross Margin 70.7% 67.0%
Operating Margin 27.6% 43.7%
Return on Equity 68.0% 36.4%
Dividend Yield 0% 0%
FCF Yield 4.52% 1.81%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
ABBV β€” AbbVie Inc.
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
AVGO β€” Broadcom Inc.
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a business split nearly evenly between these two segments. The company benefits from a durable competitive moat driven by customer concentration in mission-critical infrastructure, high switching costs, and a broad portfolio spanning semiconductors and infrastructure software. Broadcom h…
Accumulation Zones
Metric ABBV AVGO
Zone Low $198.23 $167.95
Zone High $224.66 $190.34
In Buy Zone? No No
← ABBV Research    AVGO Research β†’    All Research